Kuna njia kadhaa za kutibu kansa ya tezi-kibofu, ikitegemea hatua na ukali wa kansa hiyo, na pia afya ya mgonjwa kwa ujumla na mapendezi yake.
Baadhi ya matibabu ya kawaida ni pamoja na:
1. Ufuatiliaji wenye bidii: Mbinu hii inahusisha kufuatilia kansa kwa ukaribu kwa kufanya uchunguzi na majaribio ya kawaida, badala ya kuanza matibabu mara moja.
Inaweza kufaa kwa wanaume walio na kansa ya tezi-kibofu ya hatari ya chini.
2. Upasuaji: Upasuaji wa kuondoa tezi-kibofu ni upasuaji wa kuondoa tezi-kibofu.
Inaweza kufanywa kupitia upasuaji wa wazi au kwa njia ya laparoscopic (kwa kutumia vipande vidogo na vifaa maalum).
3. Tiba ya mnururisho: Tiba hii hutumia mnururisho wenye nishati kubwa kuua chembe za kansa.
Inaweza kutolewa kwa njia ya nje (kutoka kwenye mashine iliyo nje ya mwili) au kwa njia ya ndani (kupitia viungo vilivyowekwa karibu na uvimbe).
4. Tiba ya homoni: Tiba hii hupunguza viwango vya homoni za kiume (androgens) mwilini, ambazo zaweza kupunguza au kuzuia ukuzi wa kansa ya tezi-kibofu.
Inaweza kutumiwa peke yake au kuunganishwa na matibabu mengine.
5. Tiba ya kemikali: Tiba hii hutumia dawa kuua chembe za kansa.
Inaweza kutumiwa kwa kansa ya tezi- tezi iliyoendelea ambayo imeenea kwenye sehemu nyingine za mwili.
6. Tiba ya kinga: Tiba hii husaidia mfumo wa kinga kupigana na kansa.
Inaweza kutumiwa kwa kansa ya tezi-kibofu iliyoendelea ambayo haijaitikia matibabu mengine.
7. Tiba inayolengwa: Tiba hii inalenga jeni au protini hususa ambazo husaidia chembe za kansa kukua na kuishi.
Inaweza kutumiwa kwa kansa ya tezi-kibofu iliyoendelea ambayo haijaitikia matibabu mengine.
8. Matibabu ya baridi kali: Matibabu hayo hutumia baridi kali sana kufungia na kuua chembe za kansa.
Inaweza kutumiwa kwa saratani ya tezi- tezi ya mapema au kwa saratani ambayo imerudi baada ya matibabu mengine.
9. High-intensity focused ultrasound (HIFU): Matibabu haya hutumia mawimbi ya sauti ya masafa ya juu kupasha joto na kuharibu chembe za kansa.
Inaweza kutumiwa kwa saratani ya tezi- tezi ya mapema au kwa saratani ambayo imerudi baada ya matibabu mengine.
10. Kusubiri kwa uangalifu: Mbinu hii inahusisha kufuatilia kansa kwa ukaribu kwa kufanya uchunguzi na majaribio ya kawaida, lakini si kuanza matibabu isipokuwa dalili ziwe zimeonekana au zibadilike.
Inaweza kufaa kwa wanaume wazee wenye kansa ya tezi- tezi inayokua polepole na hali nyingine nzito za afya.
Ni muhimu kujadili chaguzi zote za matibabu na timu ya utunzaji wa afya ili kuamua njia bora ya kutenda kwa kila kesi ya kibinafsi.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
Kanusho la dhima: matibabu
Tovuti hii hutolewa kwa madhumuni ya elimu na habari tu na si kutoa ushauri wa matibabu au huduma za kitaaluma.
Habari inayotolewa haipaswi kutumiwa kugundua au kutibu tatizo la afya au ugonjwa, na wale wanaotafuta ushauri wa kibinafsi wa kitiba wanapaswa kushauriana na daktari aliye na leseni.
Tafadhali kumbuka mtandao wa neva ambao hutengeneza majibu ya maswali, ni hasa usio sahihi linapokuja maudhui ya nambari. Kwa mfano, idadi ya watu waliogunduliwa na ugonjwa fulani.
Daima kutafuta ushauri wa daktari wako au mtoa huduma nyingine ya afya waliohitimu kuhusu hali ya matibabu. Kamwe kupuuza ushauri wa matibabu ya kitaaluma au kuchelewesha katika kutafuta yake kwa sababu ya kitu umesoma kwenye tovuti hii. Kama unafikiri unaweza kuwa na dharura ya matibabu, piga simu 911 au kwenda chumba cha dharura karibu mara moja. Hakuna uhusiano daktari-mgonjwa ni kuundwa na tovuti hii au matumizi yake. Wala BioMedLib wala wafanyakazi wake, wala mchangiaji yoyote ya tovuti hii, hufanya uwakilishi wowote, wazi au implicit, kuhusiana na taarifa zinazotolewa hapa au matumizi yake.
Utoaji wa dhima: hakimiliki
The Digital Millennium Copyright Act ya 1998, 17 U.S.C. § 512 (the DMCA) hutoa njia ya kurudi kwa wamiliki wa hakimiliki ambao wanaamini kuwa vifaa vinavyoonekana kwenye Mtandao vinakiuka haki zao chini ya sheria ya hakimiliki ya Merika.
Kama unaamini kwa imani nzuri kwamba maudhui yoyote au nyenzo zilizotolewa kuhusiana na tovuti yetu au huduma inakiuka hakimiliki yako, wewe (au wakala wako) unaweza kutuma sisi taarifa kuomba kwamba maudhui au nyenzo kuondolewa, au upatikanaji wake kuzuiwa.
Taarifa lazima zipelekwe kwa maandishi kwa barua pepe (tazama sehemu ya "Contact" kwa anwani ya barua pepe).
DMCA inahitaji kwamba taarifa yako ya madai ya ukiukaji wa hakimiliki ni pamoja na taarifa zifuatazo: (1) maelezo ya kazi ya hakimiliki ambayo ni madai ya ukiukaji; (2) maelezo ya madai ya ukiukaji maudhui na habari ya kutosha kuruhusu sisi kupata maudhui; (3) mawasiliano ya habari kwa ajili yenu, ikiwa ni pamoja na anwani yako, nambari ya simu na anwani ya barua pepe; (4) taarifa na wewe kuwa na imani nzuri imani kwamba maudhui katika njia alilalamika ya si mamlaka na mmiliki wa hakimiliki, au wakala wake, au na operesheni ya sheria yoyote;
(5) taarifa na wewe, saini chini ya adhabu ya ushahidi wa uongo, kwamba habari katika taarifa ni sahihi na kwamba una mamlaka ya kutekeleza haki za hakimiliki ambayo ni madai ya kukiuka;
na (6) saini ya kimwili au ya elektroniki ya mmiliki wa hakimiliki au mtu aliyeidhinishwa kutenda kwa niaba ya mmiliki wa hakimiliki.
Kushindwa kujumuisha habari zote hapo juu kunaweza kusababisha ucheleweshaji wa usindikaji wa malalamiko yako.
Mawasiliano
Tafadhali tutumie barua pepe na swali lolote / pendekezo.
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Karibu
BioMedLib hutumia kompyuta za kiotomatiki (algorithms ya kujifunza mashine) kuzalisha jozi za maswali na majibu.
Tunaanza na machapisho milioni 35 ya biomedical ya PubMed/Medline. Pia, kurasa za wavuti za RefinedWeb.
